IMUX - NASDAQ

Immunic, Inc.

Immunic, Inc.

IMUXยทNASDAQ

$14.66

+2.3%
HealthcareBiotechnology

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$144.72M
EPS-6.2400
P/E Ratio-2.35
Earnings Date08/06/2026
Immunic, Inc.

Immunic, Inc. Fair Value Envelope

IMUX ยท NASDAQ

Our analysis suggests that IMUX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14.665, this represents a potential HIDDEN relative to our calculated worth for Immunic, Inc..

HIDDEN
Intrinsic Value
Current Price: $14.665

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$546.0M
+ Cash & Equivalents$15.5M
Firm Value-$530.5M
- Debt$684.0K
Equity Value-$531.2M
/ Shares Outstanding98,650,590B
DCF Value-$5
OVERVALUED BY 137%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$84.9M
-$83.9M
-$83.0M
-$82.1M
-$81.2M
-$80.3M
-$79.4M
-$78.5M
-$77.7M
-$76.8M
Maintenance CapEx
-$31.8K
-$31.5K
-$31.1K
-$30.8K
-$30.5K
-$30.1K
-$29.8K
-$29.5K
-$29.1K
-$28.8K
Owner Earnings
-$84.9M
-$84.0M
-$83.0M
-$82.1M
-$81.2M
-$80.3M
-$79.4M
-$78.6M
-$77.7M
-$76.8M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$78.6M
-$72.0M
-$65.9M
-$60.4M
-$55.3M
-$50.6M
-$46.3M
-$42.4M
-$38.9M
-$35.6M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your IMUX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.